Receptors, Purinergic P2Y12

"Receptors, Purinergic P2Y12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A subclass of purinergic P2Y receptors that have a preference for ADP binding and are coupled to GTP-BINDING PROTEIN ALPHA SUBUNIT, GI. The P2Y12 purinergic receptors are found in PLATELETS where they play an important role regulating PLATELET ACTIVATION.

Descriptor ID	D058925
MeSH Number(s)	D12.776.543.750.695.700.720.500.300 D12.776.543.750.720.700.720.750.300
Concept/Terms	Receptors, Purinergic P2Y12 Receptors, Purinergic P2Y12 P2Y12 Receptors, Purinergic Purinergic P2Y12 Receptors Purinergic Receptor P2Y, G-Protein Coupled, 12 Purinoceptor P2Y12 P2Y12, Purinoceptor P2Y12 Purinoceptors Purinoceptors, P2Y12 P2Y(ADP) Receptor P2Y(T) Receptor P2Y12 Purinoceptor Purinoceptor, P2Y12 Purinoceptor P2T P2T, Purinoceptor Purinergic Receptor P2Y12 P2Y12, Purinergic Receptor P2T Purinoceptor Purinoceptor, P2T

Below are MeSH descriptors whose meaning is more general than "Receptors, Purinergic P2Y12".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, G-Protein-Coupled [D12.776.543.750.695]
Receptors, Purinergic [D12.776.543.750.695.700]
Receptors, Purinergic P2 [D12.776.543.750.695.700.720]
Receptors, Purinergic P2Y [D12.776.543.750.695.700.720.500]
Receptors, Purinergic P2Y12 [D12.776.543.750.695.700.720.500.300]
Receptors, Neurotransmitter [D12.776.543.750.720]
Receptors, Purinergic [D12.776.543.750.720.700]
Receptors, Purinergic P2 [D12.776.543.750.720.700.720]
Receptors, Purinergic P2Y [D12.776.543.750.720.700.720.750]
Receptors, Purinergic P2Y12 [D12.776.543.750.720.700.720.750.300]

Below are MeSH descriptors whose meaning is related to "Receptors, Purinergic P2Y12".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Purinergic P2Y12".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Purinergic P2Y12" by people in this website by year, and whether "Receptors, Purinergic P2Y12" was a major or minor topic of these publications.

Bar chart showing 12 publications over 7 distinct years, with a maximum of 4 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2011	0	3	3
2012	0	1	1
2013	3	1	4
2015	1	0	1
2016	1	0	1
2018	0	1	1

Below are the most recent publications written about "Receptors, Purinergic P2Y12" by people in Profiles.

Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, Frelinger AL. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529.

View in: PubMed
Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, Michelson AD, Frelinger AL, Przyklenk K. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9.

View in: PubMed
Yanachkov IB, Chang H, Yanachkova MI, Dix EJ, Berny-Lang MA, Gremmel T, Michelson AD, Wright GE, Frelinger AL. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18.

View in: PubMed
Kakouros N, Kickler TS, Laws KM, Rade JJ. Hematocrit alters VerifyNow P2Y12 assay results independently of intrinsic platelet reactivity and clopidogrel responsiveness. J Thromb Haemost. 2013 Oct; 11(10):1814-22.

View in: PubMed
Sorkin GC, Dumont TM, Wach MM, Eller JL, Mokin M, Natarajan SK, Baxter MS, Snyder KV, Levy EI, Hopkins LN, Siddiqui AH. Carotid artery stenting outcomes: do they correlate with antiplatelet response assays? J Neurointerv Surg. 2014 Jun; 6(5):373-8.

View in: PubMed
Chang H, Shih LY, Michelson AD, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH, Tang TC. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7.

View in: PubMed
Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026.

View in: PubMed
Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35.

View in: PubMed
Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55.

View in: PubMed
Chang H, Yanachkov IB, Dix EJ, Li YF, Barnard MR, Wright GE, Michelson AD, Frelinger AL. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80.

View in: PubMed

People

Explore

Similar Concepts

Top Journals